The global cystic fibrosis therapeutics market was valued at $4,615.4 million in 2018 and is expected to reach $9,277.3 million by 2026, registering a CAGR of 9.2% from 2019 to 2026. Cystic fibrosis is a progressive, hereditary disease that led to insistent lung infections and limits the patient’s ability to breathe over time. Diagnosis of cystic fibrosis is a multistep process, and includes a newborn screening, a sweat test, a genetic or carrier test, and a clinical evaluation. Though people diagnosed with the disease are of age of 2, some are also diagnosed as adults. A specialist can order a sweat test and recommend additional testing to confirm the diagnosis.
Significant rise in incidence of cystic fibrosis across the globe and increase in awareness about its diagnosis are the major factors driving the market growth. In addition, rise in R&D investments by the key players such as Vertex Pharmaceuticals propels the growth of cystic fibrosis therapeutics market. However, high cost of the cystic fibrosis treatment and introduction of generic drugs hinder the growth of the market. Moreover, development of the healthcare industry and increase in R&D activities undertaken by key players are expected to boost the market growth during the forecast period. Furthermore, rise in prevalence of cystic fibrosis has generated need for newer and advanced therapeutics for its treatment. Thereby, this has led to increase in number of pipeline drugs in the market, which is expected to provide remunerative opportunities for market expansion during the forecast period.
The global cystic fibrosis therapeutic market is segmented based on drug class, route of administration, top selling drug, and region. On the basis of drug class, the market is divided into pancreatic enzyme supplements, mucolytic, bronchodilators, and CFTR modulators. Depending on route of administration, it is classified into oral and inhaled. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
KEY MARKET SEGMENTS
By Drug Class
By Route of Administration
By Region
LIST OF KEY PLAYERS PROFILED IN THE REPORT
Significant rise in incidence of cystic fibrosis across the globe and increase in awareness about its diagnosis are the major factors driving the market growth. In addition, rise in R&D investments by the key players such as Vertex Pharmaceuticals propels the growth of cystic fibrosis therapeutics market. However, high cost of the cystic fibrosis treatment and introduction of generic drugs hinder the growth of the market. Moreover, development of the healthcare industry and increase in R&D activities undertaken by key players are expected to boost the market growth during the forecast period. Furthermore, rise in prevalence of cystic fibrosis has generated need for newer and advanced therapeutics for its treatment. Thereby, this has led to increase in number of pipeline drugs in the market, which is expected to provide remunerative opportunities for market expansion during the forecast period.
The global cystic fibrosis therapeutic market is segmented based on drug class, route of administration, top selling drug, and region. On the basis of drug class, the market is divided into pancreatic enzyme supplements, mucolytic, bronchodilators, and CFTR modulators. Depending on route of administration, it is classified into oral and inhaled. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
- Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Drug Class
- Pancreatic Enzyme Supplements
- Mucolytic
- Bronchodilators
- CFTR Modulators
By Route of Administration
- Oral
- Inhaled
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Genentech, Inc.
- Novartis AG
- Gilead Sciences, Inc.
- Vertex Pharmaceuticals Incorporated
- AbbVie Inc.
- GlaxoSmithKline Plc.
- Johnson & Johnson
- Allergan plc.
- Pharmaxis Ltd.
- Mylan N.V.
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
Chapter 4: Cystic Fibrosis Therapeutics Market, By Drug Class
Chapter 5: Cystic Fibrosis Therapeutics Market, By Route Of Administration
Chapter 6: Cystic Fibrosis Therapeutics Market, By Region
Chapter 7: Company Profiles
Executive Summary
According to the report titled, 'Cystic Fibrosis Therapeutics Market by Drug Class and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2018-2026', the global cystic fibrosis therapeutics market size is expected to reach $9,277 million by 2026, registering a CAGR of 9.2% from 2019 to 2026, in terms of value.Cystic fibrosis is a hereditary disease that majorly affects the lungs and digestive system. In cystic fibrosis, the body produces thick and sticky mucus that may block the lungs and impede the pancreas. The disease can be lethal, and patients tend to have a shorter-than-normal life span. Further, the disease is so dangerous that all newborns in the U.S. are screened for CF. Moreover, there is no cure for cystic fibrosis, but taking proper nutrition and medications to thin excess mucus produced in lungs & kidney can help in increasing patient’s lifespan. In addition, treatment of cystic fibrosis includes the use of drugs such as Pulmozyme, Kalydeco, and others. These drugs can be administered to the patient by different routes such as oral and by inhalation.
Rise in incidence of cystic fibrosis across the globe and increase in medications against cystic fibrosis are the major factors driving the market growth. Moreover, rise in R&D investments toward the development of drugs to treat cystic fibrosis propels the cystic fibrosis therapeutics market growth. However, high cost of the cystic fibrosis treatment and introduction of generic drugs hinder the growth of the market. Moreover, development of the healthcare industry in the developing economies are expected to create lucrative opportunities in the near future. Furthermore, rise in prevalence of cystic fibrosis has generated need for newer and advanced therapeutics for its treatment. Hence, this has led to increase in number of pipeline drugs in the market, which is expected to provide remunerative opportunities for market expansion during the forecast period.
By cystic fibrosis therapeutics market analysis, based on drug class, the CFTR modulators segment dominated the market in 2018 and is anticipated to continue its dominance during the forecast period. This is attributed to increased usage of these drugs for the treatment of cystic fibrosis. Further, these drugs target the production and function of the mutant CFTR protein. In addition, the CFTR protein regulates the flow of water and chloride in and out of cells lining the lungs and other organs. These drugs are being considered as potent therapeutics for the treatment of the disease. The three major types of modulators are potentiators, correctors, and amplifiers.
By route of administration, oral segment accounted for the majority of market share in 2018, owing to increased formulation of cystic fibrosis therapeutics in oral form. Further, there are currently three CFTR modulator drugs approved by the U.S. FDA, all of which are oral tablets. These include ivacaftor (kalydeco), orkambi and symdeko. As per the current cystic fibrosis therapeutics market trend, the oral route of administration is estimated to grow at the fastest growth rate during the forecast period.
Key Findings of the Cystic Fibrosis Therapeutics Market:
By drug class, the CFTR segment accounted for the highest market share of 65% in 2018 and is anticipated to grow at the fastest rate during the forecast period.
By region, Europe was the major shareholder and accounted for the highest share of 33% in 2018.
By route of administration, oral segment is expected to grow at a CAGR of 9.9% during the forecast period.
North America is anticipated to grow at the fastest CAGR of 9.8% during the forecast period.
Key players operating in cystic fibrosis therapeutic markets are Genentech, Inc., Novartis AG, Gilead Sciences, Inc., Vertex Pharmaceuticals Incorporated, AbbVie Inc., GlaxoSmithKline Plc., Johnson & Johnson, Allergan plc, Pharmaxis Ltd., and Mylan N.V.
Companies Mentioned
- Genentech Inc.
- Novartis AG
- Gilead Sciences Inc.
- Vertex Pharmaceuticals Incorporated
- AbbVie Inc.
- GlaxoSmithKline Plc.
- Johnson & Johnson
- Allergan plc
- Pharmaxis Ltd.
- Mylan N.V.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 187 |
| Published | November 2019 |
| Forecast Period | 2018 - 2026 |
| Estimated Market Value ( USD | $ 4615.4 million |
| Forecasted Market Value ( USD | $ 9277.3 million |
| Compound Annual Growth Rate | 9.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
